![]() Immatics Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. | ![]() Alexion Pharmaceuticals Alexion (also known as Alexion, AstraZeneca Rare Disease) is a biopharmaceutical company engaged in therapies for rare diseases. | |||
Founding Date | Founding Date 2001 | Founding Date N/A | Founding Date 1992 | Founding Date 1977 |
Type | Type Private | Type Public | Type Public | Type Private |
Tags | ||||
Locations | Locations Utrecht, NL HQ Utrecht, NL | Locations Tübingen, DE HQ Frankfurt Am Main, DE München, DE Houston, US | Locations Boston, US HQ Frenchs Forest, AU Wien, AT Elsene, BE São Paulo, BR Vaughan, CA Shanghai, CN see more | Locations Tourcoing, FR HQ Mouvaux, FR |
Employees | Employees 28 | Employees 29723% increase | Employees 10,6006% increase | Employees 901 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.1 b | Valuation ($) 40.3 b | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) €48.3m (FY, 2025) | Revenue (est.) $6.1b (FY, 2020) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $553.5m (FY, 2020) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit €53m (FY, 2025) | Gross profit $5.5b (FY, 2020) | Gross profit N/A |
Net income | Net income N/A | Net income (€196.4m) (FY, 2025) | Net income $603.4m (FY, 2020) | Net income N/A |
Funding | ||||
Total funding raised | Total funding raised $ 210.3m | Total funding raised $ 267.3m | Total funding raised N/A | Total funding raised N/A |

Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer.
View company
Alexion (also known as Alexion, AstraZeneca Rare Disease) is a biopharmaceutical company engaged in therapies for rare diseases.
View companyMacopharma is a provider of blood transfusion and bio-sourced therapies.
View company